Less than a month after announcing an $8 million closing, San Diego, CA-based start-up Anaphore has pulled in another $13 million and three new investors. This brings the total proceeds for its series A venture round to $38 million. New investors SR One, Merck Serono Ventures and Aravis have joined existing investors 5AM Ventures, Versant Ventures and Apposite Capital.
The funds will be used to advance the development of the company's protein therapeutics pipeline. "We are delighted to have the backing of these experienced biotechnology investors and look forward to their contribution as we pursue development of our novel therapeutics to treat critical patient needs," said Dr. Katherine Bowdish, CEO of Anaphore. "The additional funds will markedly enhance our efforts to rapidly progress to the clinic."
Things are looking very promising for the young biotech. The company also announced that Dr. Simeon George, partner at SR One--GlaxoSmithkline's corporate venture fund--has joined Anaphore's Board of Directors. "SR One, Merck Serono Ventures, and Aravis are pleased to join a distinguished group of investors and support Anaphore as it seeks to improve patient care through the development of Atrimer therapeutics, proteins which we believe are highly differentiated from existing drugs and can provide significant improvements in treating a variety of diseases," said Dr. George.
- check out the Anaphore release